JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


The Journal of Nuclear Medicine Vol. 19 No. 5 476-479
© 1978 by Society of Nuclear Medicine
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Buell, U.
Right arrow Articles by Gahr, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Buell, U.
Right arrow Articles by Gahr, H.

Computerized Transaxial Tomography and Cerebral Serial Scintigraphy in Intracranial Tumors—Rates of Detection and Tumor-Type Identification: Concise Communication

Udalrich Buell, Hans P. Niendorf, Ekkehard Kazner, Wolfgang Lanksch, Jochen Wilske, Harald Steinhoff and Hannelore Gahr

University of Munich, Munich, Federal Republic of Germany

Correspondence: For reprints contact: U. Buell, Radiologische Klinik, Klinikum Grosshadern, University of Munich, Marchioninistr. 15, 8000 Munich 70, Fed. Rep. Germany.

ABSTRACT

In 215 cases of intracranial tumors with subsequent histological identification, computerized transaxial tomography (CTT), and cerebral serial scintigraphy (CSS) with [99mTc] pertechnetate were carried out to compare the efficiency of each method in detecting and classifying such tumors. With a tumor detection rate of 99%, CTT turned out to be superior to CSS (91%). On the other hand, CSS findings enhanced the CTT rate of correctly identified tumor types in meningiomas from 85 to 92% and in high-grade gliomas from 82 to 89%. In metastases, low-grade gliomas, and various other tumors, CSS supported CTT by confirming a number of these tumor types. Therefore, the most important use of CSS in intracranial tumors today is its role as a supplement to CTT in order to establish and confirm type-specific diagnoses.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 1978 by the Society of Nuclear Medicine.